loading page

Feasibility of Therapeutic Drug Monitoring of Sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer
  • +8
  • Khushboo Gandhi,
  • Amit Joshi,
  • Parsshava Mehta,
  • Murari Gurjar,
  • Pallavi Rane,
  • Jyoti Sharma,
  • Anand Patil,
  • Manjunath Nookala,
  • Vanita Noronha,
  • Kumar Prabhash,
  • Vikram Gota
Khushboo Gandhi
Advanced Centre for Treatment Research and Education in Cancer

Corresponding Author:gandhik19@gmail.com

Author Profile
Amit Joshi
Tata Memorial Hospital
Author Profile
Parsshava Mehta
Advanced Centre for Treatment Research and Education in Cancer
Author Profile
Murari Gurjar
Advanced Centre for Treatment Research and Education in Cancer
Author Profile
Pallavi Rane
Advanced Centre for Treatment Research and Education in Cancer
Author Profile
Jyoti Sharma
Advanced Centre for Treatment Research and Education in Cancer
Author Profile
Anand Patil
Advanced Centre for Treatment Research and Education in Cancer
Author Profile
Manjunath Nookala
Advanced Centre for Treatment Research and Education in Cancer
Author Profile
Vanita Noronha
Tata Memorial Hospital
Author Profile
Kumar Prabhash
Tata Memorial Hospital
Author Profile
Vikram Gota
Advanced Centre for Treatment Research and Education in Cancer
Author Profile

Abstract

High interindividual variability in pharmacokinetics coupled with concentration-effect relationship make sunitinib an ideal candidate for therapeutic drug monitoring (TDM). The feasibility of TDM of sunitinib in patients with metastatic renal cell carcinoma (mRCC) was evaluated in this prospective observational study. Seventy patients with mRCC treated with sunitinib 50mg OD were enrolled. Total trough levels (TTL) of sunitinib and N-desethyl sunitinib were measured between days 10-14 of cycle 1. The discriminatory potential of TTL of sunitinib for the prediction of responders and occurrence of grade ≥3 toxicity was determined using receiver operating characteristic (ROC) curve. Threshold concentrations obtained from ROC analysis showed that TTL ≥60.75ng/mL was associated with higher response rates and TTL ≥82.3ng/mL was associated with higher incidence of grade ≥3 toxicity compared with lower exposures (31/34 versus 5/12, P=0.001 and 9/24 versus 4/36; P=0.024 respectively). More than 50% of patients in our cohort attained TTL outside the optimal range of 60.75-82.3 ng/mL demonstrating the feasibility of TDM.
19 Apr 2022Published in Cancer Chemotherapy and Pharmacology. 10.1007/s00280-022-04432-4